TICKERNERD
Menu
SXTPSXTPHealthcare · Biotechnology

SXTP Stock Forecast: 60 Degrees Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.11
−1.77% on the day

The 2 Wall Street analysts covering 60 Degrees Pharmaceuticals, Inc. hold a median 12-month price target of $3.7 — +233.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.0M
Ticker Nerd rank
30 / 100
Median analyst target
$3.70
Analysts covering
2
Total return, dividends reinvested
1W
−7.1%
1M
−29.3%
YTD
−45.4%
1Y
−78.7%
From 52W high
−84.6%
From 52W low
+2.8%
$1.08
$7.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SXTP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 60 Degrees Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
64
Revisions
62
Momentum
30
Value
28
Accruals
27
Issuance
25
Volatility
22
Quality
17

Size (98): Smaller than most of the companies we track.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SXTP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SXTP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Oct 25Jan 26Apr 26Jul 26SXTPHigh $3.70Median $3.70Low $3.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $3.70Median $3.70High $3.70

The green dot is the last close — the median target sits +233.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2026Ascendiant CapitalMaintainsBuy$4.20 → $3.70
20 May 2026HC Wainwright & Co.DowngradeNeutral—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Jan 2026HC Wainwright & Co.MaintainsBuy—
28 Nov 2025Ascendiant CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.AssumesBuy$6.00
3 Sept 2025Ascendiant CapitalMaintainsBuy—
2 June 2025Ascendiant CapitalMaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
25 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
10 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
23 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
11 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
15 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
13 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
6 June 2024HC Wainwright & Co.ReiteratesNeutral—
3 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
20 Oct 2023HC Wainwright & Co.InitiatesNeutral—
2 Oct 2023Ascendiant CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SXTP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SXTP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

60 Degrees Pharmaceuticals, Inc. (SXTP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.7×

Cheaper than 48% of US stocks

Price / sales
3.3×

Cheaper than 39% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
−1.5×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−32.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−0.9%

Higher than 34% of US stocks

Gross margin
47.1%

Higher than 59% of US stocks

Operating margin
−1092.4%

Higher than 5% of US stocks

Net margin
22.3%

Higher than 84% of US stocks

Returns & dividend
Return on equity
−332.9%

Higher than 5% of US stocks

Return on assets
−127.1%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SXTP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SXTP60 Degrees Pharmaceuticals, Inc.$4.0M
30
HCWBHCW Biologics Inc.$4.0M
66
XRTXXORTX Therapeutics, Inc.$3.8M
15
SPRCSciSparc Ltd.$3.8M
24
PPCBPropanc Biopharma, Inc.$3.8M
41
SILOSilo Pharma, Inc.$4.2M
24
REVBRevelation Biosciences, Inc.$4.3M
8

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 60 Degrees Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SXTP news & analysis

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

GlobeNewsWire · 14 Aug 2026positive

60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, ended June 30, 2026. Net product revenues increased approximately 106% to approximately $208 thousand, up from approximately $101 thousand in the second quarter of 2025.

Why it matters — A SXTP watcher would care because the company reported a substantial increase in net product revenues for the quarter, indicating improved commercial performance for its vector-borne disease medicines.

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire · 30 July 2026neutral

60 Degrees Pharmaceuticals announced a private placement, issuing 574,713 shares of common stock (or pre-funded warrants) along with series A and short-term series B warrants at a purchase price of $1.74 per share, with the warrants exercisable at $1.49 per share upon issuance.

Why it matters — SXTP watchers would care because this private placement represents a capital raise that could dilute existing shareholders while potentially providing the company with additional funding for its vector-borne disease drug pipeline.

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

GlobeNewsWire · 29 July 2026neutral

60 Degrees Pharmaceuticals announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis, with results to be disclosed by October 6, 2026. The company plans to request an FDA meeting after the interim readout to discuss the regulatory pathway for a New Drug Application for tafenoquine in babesiosis.

Why it matters — This milestone brings 60 Degrees Pharmaceuticals closer to a potential FDA meeting and possible NDA submission for tafenoquine in babesiosis, a key pipeline candidate for the company.

FAQ

Frequently asked questions about SXTP stock

What is the SXTP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering 60 Degrees Pharmaceuticals, Inc. have a median 12-month price target of $3.7, with estimates ranging from $3.7 to $3.7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SXTP stock a buy right now?

Of the 2 analysts covering 60 Degrees Pharmaceuticals, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 60 Degrees Pharmaceuticals, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SXTP?

As at 22 Aug 2026, 60 Degrees Pharmaceuticals, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will SXTP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +233.3% from the last close, and Ticker Nerd's factor model ranks 60 Degrees Pharmaceuticals, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SXTP stock forecast for 2030?

No analyst covering 60 Degrees Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $3.7 over the next 12 months.

How has SXTP stock performed over the past year?

60 Degrees Pharmaceuticals, Inc. returned -78.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 60 Degrees Pharmaceuticals, Inc. do?

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing medicines for the treatment and prevention of vector-borne and infectious diseases.

What is the latest news on SXTP?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results". 60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, ended June 30, 2026. Net product revenues increased approximately 106% to approximately $208 thousand, up from approximately $101 thousand in the second quarter of 2025.

Company

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing medicines for the treatment and prevention of vector-borne and infectious diseases. Its primary product, ARAKODA (tafenoquine), is an FDA-approved antimalarial for malaria prophylaxis in adults 18 years and older, featuring a dosing regimen with a loading phase, weekly doses during exposure, and a final dose post-travel, available through prescription in the United States and Australia as KODATEF. The company sponsors clinical trials exploring tafenoquine for babesiosis, a tick-borne parasitic illness, including studies on relapsing, hospitalized, and chronic cases, addressing unmet needs where no specific FDA-approved treatments exist. 60 Degrees Pharmaceuticals Inc. also pursues research into other vector-borne conditions like those linked to Lyme disease pathogens through collaborations with academic institutions in the United States, Australia, and Singapore. Founded in 2010 and headquartered in Washington, D.C., with research and development in Australia, it operates in the pharmaceuticals and biotechnology sector, emphasizing tafenoquine-based therapies for diseases transmitted by mosquitoes and ticks.

CEO Dr. Geoffrey Stuart Dow Ph.D. · 3 employees · United States · https://www.60degreespharma.com